Kyverna Therapeutics, INC 8-K filings

Kyverna Therapeutics announced second quarter 2026 financial results, highlighting FDA RMAT designation for miv-cel in naSPMS and progress on BLA submission for SPS.

Kyverna Therapeutics and ElevateBio have entered into a Clinical and Commercial Supply Agreement to secure manufacturing for Kyverna's lead cell therapy candidate, miv-cel.

Kyverna Therapeutics has amended its loan and security agreement with Oxford Finance LLC, extending loan availability and modifying milestone-based draw conditions.

Kyverna Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of two Class II directors and the ratification of its independent auditor.

Kyverna Therapeutics announced the appointment of Gregory Martini as its new Chief Financial Officer, effective May 18, 2026, succeeding Marc Grasso.

Kyverna Therapeutics announces the appointment of Nadia Dac as Chief Commercial Officer, effective May 4, 2026, to lead commercial strategy for miv-cel.

Kyverna Therapeutics announced positive longer-term follow-up data from its Phase 2 trial of miv-cel in generalized myasthenia gravis and primary analysis results from its registrational trial in stiff person syndrome.

Kyverna Therapeutics announced positive longer-term Phase 2 data for its miv-cel therapy in generalized myasthenia gravis, showing deep and durable responses.

Kyverna Therapeutics reported strong clinical progress for its autoimmune CAR T programs, including a planned BLA submission for stiff person syndrome in 1H 2026, and extended its cash runway into 2028.

Kyverna Therapeutics appointed Sravan Emany and Andrew Miller to its Board of Directors, bringing extensive financial, strategic, and drug development expertise as the company advances its cell therapies.

Kyverna Therapeutics announced the retirement of its Chief Technology Officer, Karen Walker, and the appointment of Mayo Pujols as her successor, alongside an increase of 1,000,000 shares to its 2024 Inducement Equity Incentive Plan.

Kyverna Therapeutics announced a corporate update, outlining 2026 strategic priorities, appointing Christi Shaw as Executive Chairperson, and reporting preliminary year-end 2025 financials.

Kyverna Therapeutics announced the pricing of an underwritten public offering of 13,333,333 shares of common stock at $7.50 per share, expecting to raise approximately $100 million in gross proceeds.

Kyverna Therapeutics announced positive topline data from its registrational Phase 2 KYSA-8 trial of mivocabtagene autoleucel (miv-cel) in stiff person syndrome, demonstrating statistically significant clinical benefit across all primary and secondary endpoints.

Kyverna Therapeutics announced positive topline data from its registrational Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome, showing statistically significant clinical benefit.

Kyverna Therapeutics provides a business update, narrows the timeline for stiff person syndrome trial data, reports positive generalized myasthenia gravis data, and secures a $150 million loan facility.

Kyverna Therapeutics secured up to $150 million in non-dilutive financing from Oxford Finance and advanced the expected readout for its stiff person syndrome trial to early 2026.

Kyverna Therapeutics announced positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis, demonstrating robust efficacy and a manageable safety profile.

Kyverna Therapeutics announced positive interim Phase 2 data for its KYV-101 therapy in generalized myasthenia gravis, demonstrating 100% clinically meaningful responses.

Kyverna Therapeutics announces the resignation of Dr. Steve Liapis from its Board of Directors, effective September 30, 2025, with Christi Shaw appointed to the Audit Committee.

Kyverna Therapeutics provides a business update and second quarter 2025 financial results, highlighting progress in its neuroimmunology CAR T franchise and a strong cash position.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company, has appointed Marc Grasso, M.D., as its new Chief Financial Officer, effective June 30, 2025, succeeding Ryan Jones who transitions to a strategic advisor role.

Kyverna Therapeutics, Inc. announced the successful election of two Class I directors and the ratification of BDO USA, P.C. as its independent auditor at its 2025 Annual Meeting of Stockholders.

Kyverna Therapeutics reports progress in clinical trials for KYV-101 in stiff person syndrome and myasthenia gravis, anticipates BLA filing in 1H 2026, and has a cash runway into 2027.

Kyverna Therapeutics reports financial results for 2024 and provides a business update, highlighting progress in clinical trials for autoimmune diseases and a cash runway into 2027.

Kyverna Therapeutics has entered into an agreement with Jefferies LLC to potentially sell up to $50 million of its common stock through an open market offering.

Kyverna Therapeutics has appointed Naji Gehchan as Chief Medical and Development Officer to lead research, clinical development, and medical affairs.

Kyverna Therapeutics announces its 2025 strategic priorities, focusing on advancing its CAR T therapies for autoimmune diseases, with a key milestone being a BLA filing for stiff person syndrome targeted for 2026.

Kyverna Therapeutics' Chief Medical Officer, James Chung, resigned effective November 22, 2024, and entered into a severance agreement with the company.

Kyverna Therapeutics announced its third quarter 2024 financial results, highlighted by a strong cash position of $321.6 million and advancements in its KYV-101 clinical development program.